Weekly Research Analysts’ Ratings Updates for Merus (MRUS)

Merus (NASDAQ: MRUS) recently received a number of ratings updates from brokerages and research firms:

  • 6/11/2018 – Merus was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 5/30/2018 – Merus was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 5/25/2018 – Merus was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/24/2018 – Merus was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 5/14/2018 – Merus was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/9/2018 – Merus was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “
  • 5/4/2018 – Merus was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “
  • 4/30/2018 – Merus had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $32.00 price target on the stock, up previously from $26.00.
  • 4/27/2018 – Merus was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Merus stock traded up $0.30 during trading hours on Tuesday, reaching $19.41. 11,467 shares of the company’s stock traded hands, compared to its average volume of 22,104. Merus NV has a fifty-two week low of $13.23 and a fifty-two week high of $21.94. The company has a market cap of $429.83 million, a PE ratio of -4.52 and a beta of 0.13.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, April 26th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter. Merus had a negative net margin of 530.70% and a negative return on equity of 91.14%. The business had revenue of $4.49 million for the quarter. research analysts expect that Merus NV will post -3.67 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in MRUS. Deutsche Bank AG lifted its position in Merus by 146.6% during the 4th quarter. Deutsche Bank AG now owns 9,400 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 5,588 shares during the period. Bain Capital Public Equity Management LLC acquired a new stake in shares of Merus in the 4th quarter valued at approximately $8,297,000. Stanley Laman Group Ltd. acquired a new stake in shares of Merus in the 1st quarter valued at approximately $860,000. BVF Inc. IL acquired a new stake in shares of Merus in the 1st quarter valued at approximately $44,832,000. Finally, Sofinnova Ventures Inc acquired a new stake in shares of Merus in the 1st quarter valued at approximately $36,338,000. Institutional investors own 43.31% of the company’s stock.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Receive News & Ratings for Merus NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply